Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

Using 5α-reductase inhibitors for hair loss in women doesn't increase cancer risk.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

5α-Reductase inhibitors may increase depression risk but not dementia or suicide.

A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.

New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

A new compound effectively inhibits human 5α-reductase 1.

Ritlecitinib is cost-effective for severe alopecia areata in Japan.

Ritlecitinib can help about 14,000 people with severe hair loss.

JAK inhibitors can cause severe acne, limiting their use for hair regrowth.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

5α-reductase inhibitors for hair loss can cause mild, reversible sexual side effects in some men.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

JAK inhibitors are generally safe for alopecia areata and atopic dermatitis, with mostly mild side effects.